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I- Summary 
Lactobacillus rhamnosus GG (LGG) is one of the most studied probiotics strains. Due to 
production of lactic acid by LGG, the faecal pH decreases which inhibits colonization by 
potentially pathogenic bacteria. Short-term effects of LGG in infants and young children with 
infectious diarrhoea have been reported in a number of studies; however there are no 
published data supporting long-term clinical benefits of using infant formula supplemented 
with LGG. Possible long-term effects on intestinal colonization and its effects on long-term 
gastrointestinal and immune functions are unknown. LGG as an ingredient in infant formula 
and baby foods is intended for daily or regular use and not for short-term specific treatment. 
Furthermore, the targeted consumer group includes, and is partly even primarily intended to 
be, children under the age of one year. These two aspects demand particular consideration 
with regard to the unknown possible effects of long-term treatment with large doses of live 
bacteria on the ecology of the microflora, and on the immune system, particularly since these 
systems have not yet fully matured in infants and small children. There is no documented 
prophylactic effect of LGG on any diseases in children. Following careful review, The 
Norwegian Scientific Committee for Food Safety finds that the data available are insufficient 
to support the safety of LGG in infant formula and baby foods neither for healthy infants (0-
12 months), for inclusion in infant formula classified as food for special medical purposes for 
infants and children up to 12 months nor for children above 1 year when intended for use 
several times a day.  
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II- Background 
The term probiotic is derived from the Greek, meaning “for life”. Probiotics were defined by a 
group of experts of the Food and Agriculture Organization (FAO) of the United Nations and 
World Health Organization (WHO) as “live microorganisms which, when administered in 
adequate doses, confer a health benefit on the host” (Food and Agriculture Organization of the 
United Nations and World Health Organization 2001).  
 
The Scientific Committee on Food (SCF) of the European Commission recommended that 
infant formulas with probiotic microorganisms should be marketed only if their benefit and 
safety had been evaluated according to the principles outlined by the same Committee. SCF 
did not object to the addition of probiotic bacteria to follow-on formulas. The Committee 
emphasized that only bacterial strains with defined identity and genetic stability, as 
demonstrated by cultural and molecular methods, should be used. Furthermore, the identity of 
the probiotic strain should be described by molecular methods in a dossier and be available to 
food control authorities (Scientific Committee on Food.European Commission.Health and 
Consumer Protection Directorate-General. 2004). SCF recommended that for safety reasons, 
based on current knowledge, probiotics should not be given to immunocompromised or 
premature infants.   
 
The European Society of Pediatric Gastroenterology and Hepatology (ESPGHAN) Committee 
on Nutrition has recently reviewed the available information on the effects of adding probiotic 
bacteria to infant formula, follow-on-formula, and special medical foods  (Agostoni et al. 
2004). ESPGHAN recognizes that there is evidence that some probiotic preparations have 
benefits on health and well-being; for instance there are some data supporting a short-term 
benefit of some probiotic strains in infants and young children with infectious diarrhoea. 
However, ESPGHAN found that the available clinical trials contain only limited data on the 
safety and clinical effects of probiotic preparations added to infant formula, follow-on-
formula, and special medical food. ESPGHAN mentioned the lack of data regarding 
long-term clinical benefits of infant formula supplemented with probiotic bacteria, and 
long-term effects on intestinal colonization and its effects on long-term gastrointestinal (GI) 
and immune functions. 
 
Probiotics comprise an increasing group of microorganisms. The microorganisms commonly 
used as probiotics for humans belong to the Lactic Acid Bacteria (LAB), which have the 
ability to metabolise carbohydrates to lactic acid, thereby lowering the micro-environmental 
pH. The lactic acid bacteria group comprises 16 genera including Streptococcus, 
Lactobacillus, Leuconostoc, and Pediococcus. Bifidobacteria are not part of the LAB group, 
but are members of the commensal gut flora. Historically, Lactobacillus and Bifidobacterium 
associated with food have been considered safe (Adams and Marteau 1995).  Both genera of 
bacteria are considered as part of the mammalian commensal flora. Recently, Lactobacillus 
rhamnosus (LGG) has been identified as a probiotic for use in certain paediatric nutrition 
products, by Mead Johnson (USA).      
 
The Norwegian Food Safety Authority (Mattilsynet) has been asked by Nutri Konsult Täby 
(Finland) to permit the marketing of infant-formula and baby foods that have been 
supplemented with Lactobacillus rhamnosus (LGG) at a concentration of 108 CFU/g formula. 
The intention is to ensure a concentration of at least 106 CFU/g powder formula throughout 
the shelf-life of the product. The Norwegian Food Safety Authority (Mattilsynet) is not aware 
of any infant-formula or baby food containing LGG that is on the Norwegian market 
(Nutramigen is intended for infants and children > 4 months).  
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In March 2004 The Norwegian Food Safety Authority (Mattilsynet) asked the Norwegian 
Scientific Committee for Food Safety to address this issue (00/1956/touse and 
2000/1956/gyomj). In response, an ad hoc Working Group of experts was appointed with the 
mandate to draft a risk assessment regarding the use of LGG in infant-formula and baby 
foods. 
 
III- Terms of reference 
The Norwegian Scientific Committee for Food Safety (Vitenskapskomitéen for mattrygghet) 
has been asked by the Norwegian Food Safety Authority (Mattilsynet) for a risk assessment 
regarding the use of LGG in infant-formula and baby foods. 
Questions to the Norwegian Scientific Committee for Food Safety*: 
1. Is LGG, based on generally recognized data, suitable for inclusion in ordinary infant formula?  
2. Is LGG, based on generally recognized data, suitable for inclusion in infant formula classified as food 
for special medical purposes for infants 0-4 months old with the diagnosis “ cow’s milk protein and soy 
allergy”  
3. Is LGG, based on generally recognized data, suitable for inclusion in infant formula classified as food 
for special medical purposes for infants and children > 4 months?  
4. Is LGG, based on generally recognized data, suitable for inclusion in baby foods intended for use in 
healthy infants and children between 4 months and 3 years?  
 
IV- Methodology 
Data sources: We searched the MEDLINE database, 1966-2004 and Word Wide Web 
(WWW), using the various search terms, for example; probiotics, Lactobacillus, 
Lactobacillus GG, Lactobacillus rhamnosus. Furthermore, documentation had been provided 
from Mead Johnson (Finland) to the Norwegian Food Control Authority (Mattilsynet). 
Data extraction: English-language articles were selected that provided information on the 
use of probiotics and Lactobacillus GG as probiotic bacteria. 
 
V- Exposure assessment 
Industrially, some Lactobacillus species are used for the production of foods that require 
lactic acid fermentation like yoghurt and cheese, fermented vegetables (olives and pickles), 
fermented meats (salami) and sourdough bread. Lactobacilli are part of the normal flora of 
animals. During the last 10 years, strains of lactobacilli, including LGG, have been included 
in a number of probiotic products (Jay 2004).  
 
VI- Lactobacillus spp.  
Lactobacillus is a broad genus characterized by formation of lactic acid as a sole or main end 
product of carbohydrate metabolism. The production of lactic acid by Lactobacillus makes the 
environment acidic and this may inhibit the growth of some harmful bacteria. Lactobacillus is 
                                                 
* Spørsmål til Vitenskapskomittéen for mattrygghet 
Er LGG basert på generelt anerkjente data, egnet til å inngå i vanlige morsmelkerstatninger? 
Er LGG basert på generelt anerkjente data, egnet til å inngå i morsmelkerstatninger som er klassifisert som 
medisinske næringsmidler til spedbarn fra 0-4 mnd med diagnosen kumelkproteinallergi og soyaallergi? 
 Er LGG basert på generelt anerkjente data, egnet til å inngå i morsmelkerstatninger som er klassifisert som 
medisinske næringsmidler til spedbarn og barn >4 mnd? 
Er LGG basert på generelt anerkjente data, egnet til å inngå i barnemat beregnet til friske sped- og småbarn 
mellom 4 mnd. og 3 år? 
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a genus of Gram-positive microaerophilic, non-spore-forming rods or coccobacilli. Eighty 
species of Lactobacillus are recognised at present (Satokari et al. 2003). They are common, 
and usually benign, inhabitants of the bodies of humans and animals; they are, for example, 
present in the GI and the vagina (Hammes and Vogel 1995).  
 
VI-A- Lactobacillus rhamnosus GG (LGG) characteristics 
Lactobacillus rhamnosus GG (ATCC 53103) is a probiotic strain that has been isolated from 
healthy human intestinal flora. It is one of the most extensively studied probiotic lactic acid 
bacterial strains (Agarwal et al. 2003;Armuzzi et al. 2001;Baharav et al. 2004;Biller et al. 
1995;Goldin et al. 1992;Gorbach et al. 1987;Guandalini 2002). Valio Finnish Cooperative 
Dairies Association, Helsinki, Finland is a large dairy/food company that was granted 
exclusive license for LGG in 1987. 
In the human digestive system, LGG has been shown to:  
1- Tolerate intestinal conditions (i.e. stomach acidity and bile salts) and survive the passage 
through the GI tract to effectively, but temporarily, colonize the digestive tract (Goldin et al. 
1992).  
2- Adhere to the mucosa of the human intestine and colonize the human GI tract (Ahrne et al. 
1998). The colonization is believed to be transient, but long-term during continued 
administration. 
3- Produce antimicrobial substances with activity against potential pathogens such as 
Escherichia coli, streptococci, Clostridium spp., Salmonella spp. and Clostridium 
difficile(Gorbach et al. 1987;Silva et al. 1987) 
 
Using colon biopsies, the attachment of LGG to human intestinal mucosa and the persistence 
of the attachment after discontinuation of LGG administration was studied (Alander et al. 
1999;Vilpponen-Salmela et al. 2000). LGG was shown to persist in the colonic mucosa for 
2 weeks following the end of administration, although the LGG counts in the faeces were 
already below the detection level. The authors concluded that the study of faecal samples 
alone might underestimate the extent of colonization.  
 
VII- Survival kinetics 
The effectiveness of probiotics is related to their ability to survive passage through the acidic 
stomach environment and the alkaline conditions in the duodenum, as well as their ability to 
adhere to the intestinal mucosa of the colon and to colonize the colon. Lactobacillus GG is 
more prone to colonize the colon than other probiotic lactobacilli. After passage through the 
stomach and the small intestine, those probiotics that survive are transiently established in the 
colon. 
VIII- The intestine in infancy 
At birth the basic architecture of the intestine is organised, but undergoes major development 
in the first months and years of life. There is substantial immaturity of the intestine at birth 
and early nutrition may programme the enteric nervous system by stimulating release of gut-
tropic hormones. The gut has a number of important functions:  
The onward passage of the ingested food bolus; 
To mix and grind the ingested food bolus; 
Digestion of ingested food; 
Absorption of the digested nutrients into the blood and lymph vessels; 
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A major immunological function; 
A regulatory role in protein metabolism; 
Secretion of hormones; 
Absorption of water; 
Bacterial colonization and fermentation. 
 
The small intestine is a major immunological organ and the total number of lymphocytes 
within the intestine is equivalent to the number in the spleen. There is a rich representation of 
the innate immune system with cells like macrophages, eosinophils and mast cells. 
The body’s defence against potentially harmful substances and organisms is brought about by 
a combination of innate and acquired cellular and humoral immunity.  Microbial colonization 
of the intestine plays a fundamental role in the priming and maturation of the mucosal 
immune system and may also affect enterocyte function in more subtle ways.  The intestine is 
a complex organ and in infancy is still under development. There are many factors involved in 
the development of a healthy intestinal flora, normal immune responses to antigen and oral 
tolerance. This is an area for further research, at present we do not know the final 
consequences of changing one single factor in the complex environment of the intestine. 
 
IX- Intestinal microflora 
Studies in germ-free animal models have indicated that colonization of the GI-tract plays an 
important role in the development of the gut immune system (Umesaki and Setoyama 2000). 
The intestinal microflora provides essential stimuli for the diversification of the antibody 
repertoire after birth. Studies on germ-free animals indicate that a successful colonization of 
the intestine is a prerequisite for the development of a normal immune response system (Sudo 
et al. 1997)  
The human intestinal microflora is frequently discussed as if it were a defined entity. 
However, the intestinal microflora comprises a dynamic mixture of microorganisms. It has 
been observed that the predominant bacterial community attached to the colonic mucosa is 
equally distributed along the colon, but is significantly different from the faecal community. 
Host-related factors have a major impact on the bacterial composition in the human GI tract. 
Thus, every individual has a unique microflora; even homozygotic twins differ in the 
composition of their microflora (Zoetendal E.G. 2001). The intestinal microflora develops 
over time, determined by an interaction between genetic factors, contact with the 
environment, diet and disease.  
In utero the intestine is sterile, but at birth the baby acquires bacteria such as Lactobacillus, 
Bacteroides, Peptostreptococcus, and Peptococcus from the maternal birth canal (Larsen and 
Monif 2001). Subsequently, the child will be exposed to microbes from the environment. The 
first microorganisms to colonize are the facultative anaerobes, although strict anaerobes can 
also be detected from the first day after birth (Benno and Mitsuoka 1986). Genera and species 
of bacteria isolated from infant faeces include (Benno and Mitsuoka 1986;Beritzoglou 1997): 
1- Facultative anaerobes: Escherichia, Staphylococcus, Streptococcus, Enterobacter, 
Klebsiella, Proteus, Citrobacter, Pseudomonas, and Bifidobacterium. 
2- Strict anaerobes: Clostridium, Bacteriodes, Eubacterium, Veillonella, Peptococcus, and 
Peptostreptococcus, and 
3- Microaerophilic/facultative anaerobes like Lactobacillus; L. acidophilus, L. fermentum, L. 
brevis, L. salivarius, L. plantarum. 
 
Two to three days after birth, anaerobic bacteria are the main microorganisms found in the 
faeces of infants. The reason may be that facultative anaerobes reduce the redox potential in 
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the gut and render the environment suitable for obligate anaerobes. Thus, establishment of the 
gut microflora is considered a step-wise process with facultative anaerobes such as the 
enterobacteria, coliforms and lactobacilli colonizing the intestine first, rapidly succeeded by 
bifidobacteria and other lactic acid bacteria. The critical stages of gut colonization are in the 
days after birth and during weaning, as illustrated in Figure 1.   
The colonic population of breast-fed babies is dominated by bifidobacteria and other lactic 
acid bacteria, with very few Bacteroides, Clostridium, and coliforms. In contrast, more 
variation occurs in the microflora of formula-fed babies, which tend to contain larger numbers 
of Bacteroides, Clostridium, and enteric bacteria. The mechanisms responsible for the 
differences in the microflora of infants fed human milk and modern formula are numerous 
and difficult to reproduce. Immunological factors such as secretory IgA (sIgA) and lysozyme 
in human milk prevent the growth of some bacteria. The faecal pH of breast-fed infants may 
promote bacteria like Lactobacillus and Bifidobacterium, which are more acid-tolerant.   
The intestinal microflora constitutes a highly interconnected ecosystem where factors that 
modulate one aspect may have many consequences downstream of the initial events. The 
ability of the bacteria to modulate immune function, metabolise carcinogenic agents and 
provide a direct barrier to invasion of the gut by pathogenic microorganisms are examples of 
the diverse functionality conferred by the microflora. Many of these interactions and 
functionalities are still unknown or are poorly understood. It is difficult to manipulate the 
human microflora; one problem being that the composition of the intestinal microflora is quite 
different from one human to another, which is an obstacle to manipulation.  In particular, the 
consequences of LGG transfer to the intestine of infants and children by using LGG in infant-
formula and baby foods are unknown. Despite this fact, there are a number of manufacturers 
interested in establishing probiotic therapies for humans. This raises the question as to 
whether an artificial microflora could be designed to benefit babies who do not consume 
breast milk. 
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    Mixed-fed 
     Not much known, but  
              distinct from (and between)  
     breast and formula-fed 
Breast-fed         Formula-fed 
Mainly bifidobacteria/lactobacilli                                                                                 Streptococci/enterobacteriaceae/bacteroides   
 Acetic and lactic acid                                          Acetic and propionic acid 
 
           
 
 
 
 
            
         
    Weaning 
Gradual diversification of flora 
    Increase in propionic and butyric acids 
 
      
 
 
                 Adult 
   Stable mixed flora greater than 400 species in dominant flora 
     Acetic/propionic/butyric acid 
      
FIG. 1. A scheme of the development of the intestinal microflora in humans (Edwards and Parrett 2002) 
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X- Risk and safety aspects 
In healthy adult individuals, lactobacilli are natural inhabitants of the oral cavity, the ileum 
and the colon and they are the predominant microorganisms in the vagina (Shortt 2002). 
Historically, lactobacilli naturally associated with food have been considered safe with no 
pathogenic potential. However, probiotics may theoretically be responsible for some potential 
side effects like systemic infections, altered intestinal metabolism, infections, gene transfer 
and immunomodulation and adjuvant effects (Davidson and Butler 2000).  
 
X-A- Systemic infections 
The possible effects of the increased probiotic use of LGG on the occurrence of bacteraemia 
due to lactobacilli were studied in Finland between 1990-2000 (Salminen et al. 2004). Eleven 
LGG isolates were found in blood cultures from patients, without any temporary increasing 
trend that would suggest an association with the increase in the probiotic use. Most of the 
cases of infection with lactobacilli occur in patients with underlying conditions that are 
predominantly severe(Husni et al. 1997;Saxelin et al. 1996). To date, there are two cases of 
infections which have been reported and are assumed to be associated, although not 
necessarily proven, with the consumption of commercial products containing L. rhamnosus 
(Mackay et al. 1999;Rautio et al. 1999).  
The European Society of Pediatric Gastroenterology and Hepatology (ESPGHAN) (Agostoni 
et al. 2004) and the Scientific Committee on Food of the European Commission (Scientific 
Committee on Food.European Commission.Health and Consumer Protection Directorate-
General. 2004) have concluded that, based on current knowledge, probiotics should not be 
given to immunocompromised patients or premature infants.      
 
X-B- Altered metabolic activity 
There is currently limited knowledge of the enzymatic functions of microbes intended for 
probiotic use. The intestinal microflora is considered to have a metabolic capacity equalling 
the liver. In newborns the detoxification capacity of the liver is low and the margins may be 
small. It is thus essential to gain knowledge of the enzymatic properties of probiotic microbes, 
especially when they are intended for use in infants. The intestinal microflora is involved in 
the synthesis of vitamins, the conversion of cholesterol, bile acids, and the formation and 
elimination of toxic and procarcinogenic products. Microbially-derived enzymes often 
participate in reversing the detoxification processes that have taken place in the liver 
(Hawksworth et al. 1971).  This may have negative consequences, especially in newborns and 
infants, in whom the detoxification capacity of the liver is limited.    
 
X-C- Gene transfer 
Horizontal transfer of resistance/virulence genes between bacteria may occur by different 
mechanisms: 1) the acquisition of exogenous DNA containing resistance/virulence genes by 
transformation; 2) the acquisition of resistance/virulence genes by transduction mediated by 
bacteriophages; and 3) the acquisition/virulence of resistance genes on mobile genetic 
elements such as plasmids or transposons by conjugation. There are no reports concerning 
virulence factors in LGG. Bacteria belonging to genus Lactobacillus are intrinsically resistant 
to vancomycin, which means that vancomycin-susceptible strains of these species do not exist 
(Tynkkynen et al. 1998). The intrinsically vancomycin-resistant lactobacilli species, including 
LGG have not been shown to contain van genes, which encode for resistance against 
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vancomycin in enterococci and vancomycin-resistant staphylococci. It is not clear whether 
intrinsic vancomycin resistance in Lactobacillus is associated with any resistance genes. In 
clinical microbiology, the emergence of vancomycin-resistant enterococcal strains has caused 
a serious therapeutic problem, since enterococci may contain several other antibiotic-
resistance genes, vancomycin is often the only effective antibiotic for treatment. Furthermore, 
many concerns have been expressed about the possible transfer of van genes to staphylococci. 
There is no indication that intrinsically vancomycin-resistant lactobacilli can transfer 
vancomycin-resistance genes to other species.  
 
X-D- Immunomodulation and adjuvant effects  
Probiotics have, in common with other microbes and microbial products, the potential to 
modulate immune responses. They interact with so called Toll-like receptors present on cells 
belonging to the immune system. Toll-like receptors are a family of receptors involved in the 
recognition of a wide range of microbial molecules, e.g. lipopolysaccharide (LPS) for Gram-
negative bacteria and peptidoglycan for Gram-positive bacteria. Different microbes, or 
combinations of different microbes or microbial products, act through different types of Toll-
like and other receptors resulting in different end-effect signals. In accordance with such a 
model it has been reported that LGG causes different effects on the cytokine pattern, 
depending on whether it has been given alone or in combination with other probiotics 
(Pohjavuori et al. 2004).  
 
Different species within a genus may also cause opposite effects on cytokines. This is 
illustrated by studies on species within the Bifidobacterium genus (He et al. 2002).  
Knowledge of the signals by which microbes and microbial products exhibit their effects is 
relatively recent and incomplete. The mechanisms that lie behind the clinical improvement 
claimed in some conditions such as eczema is unknown. Neither the total effect of any given 
probiotic on the immune system, nor the potential negative effects such as immunomodulation 
that might result in allergy or autoimmunity, are known. In particular, inappropriate immune 
stimulation may theoretically lead to autoimmune diseases.  
 
XI- LGG for healthy infants and children 
Beneficial intestinal microflora has been shown to stimulate the normal mucosa and defence 
systems, and to inhibit pathogenic microorganisms (Dai and Walker 1999). Thus, the idea of 
controlling the process in newborn intestinal colonization is intriguing. Studies on the 
neonatal intestinal flora and the differences in colonization patterns have influenced feeding 
practices, and more recently formula development. We have provided a summary of results 
and evaluated various clinical studies, including studies referred to by Mead Johnson, 
involving consumption of LGG by healthy and compromised infants and children. 
 
XI-A- LGG and intestinal colonization    
The ability of LGG to colonize the intestine of healthy newborns (1-week to 1-month old) and 
the influence of its administration on normal microflora establishment has been studied (Sepp 
et al. 1993). According to the authors, 14 days of administration of LGG, which started right 
after birth, increased intestinal lactobacilli concentrations and did not impair the establishment 
of a normal faecal bacterial microflora. The authors concluded that the faecal 
microorganisms’ predominance pattern did not differ in 1-week and 1-month old newborns of 
 10
the LGG group. However, the concentrations of both lactobacilli and coliform bacteria were 
higher in 3-4 and 5-7 day old newborns of the LGG group than in the control group. The 
authors studied only the major bacterial species in the infant faeces and the possible presence 
of anaerobic bacteria was overlooked. Finally, the duration of the study was too short to draw 
any conclusions with regard to long-term effects. Therefore, the conclusion that LGG did not 
impair the establishment of a normal faecal bacterial microflora cannot be made. In a study 
performed by (Marini et al. 1997) significant decreases in the aerobic/anaerobic ratio was 
observed in LGG-treated children as compared to untreated pre-term children. 
The ability of the LGG to colonize the immature bowel of premature infants has been studied 
(Millar et al. 1993). The authors demonstrated that orally administrated LGG was well 
tolerated and colonized the bowel of premature infants. However, colonization with LGG did 
not reduce the faecal reservoir of potential pathogens, and there was no evidence that 
colonization gave any clinical benefit for this particular group of infants.   
 
XI-B- LGG for prevention and treatment of diarrhoea   
One of the primary areas of probiotic use in children has been in the treatment and prevention 
of diarrhoea. The positive effect of LGG in the treatment of paediatric antibiotic-associated 
diarrhoea, which is caused by Clostridium difficile, has been reported.  
Prevention 
In a Peruvian study (Oberhelman et al. 1999), 204 undernourished children, aged between 6 
and 24-months old at the study start, were given a once-daily intake of LGG, 6 days a week,  
for 15 months. The results showed a reduction in the frequency of acute diarrhoea in non-
breast-fed infants aged 18-24 months. There were, however, no detectable effects in younger 
or older children or in breast-fed infants.  
Nosocomial diarrhoea is a major problem in paediatric hospitals worldwide and is commonly 
caused by enteric viral pathogens, especially rotavirus. The effect of orally administrated 
LGG in conjunction with live oral rotavirus vaccine was tested in 2-5 month-old infants 
(Isolauri et al. 1995). Infants who received LGG showed an increased response with regard to 
rotavirus-specific IgM secreting cells, measured with an ELISPOT technique, on day 8 after 
vaccination. Both IgM and IgA seroconversion were higher in infants receiving LGG as 
compared to the placebo group. However, the authors did not study the duration of protection 
against rotavirus, and the IgM and IgA seroconversion against serogroups of rotavirus other 
than those used in the study were not measured. Measurements of the concentration of IgA 
and IgM in intestinal mucus layer and studies on cellular immunity were not performed. 
In a study performed in Poland (Szajewska et al. 2001), the efficacy of orally administered 
LGG in the prevention of nosocomial diarrhoea in hospitalised infants aged 1-36 months was 
studied. The study showed that prophylactic use of LGG significantly reduced the risk of 
nosocomial diarrhoea in infants, particularly nosocomial rotavirus gastroenteritis. The study 
did not give information regarding the effect in relation to age distribution or breast-fed 
versus formula-fed infants. 
Different lactic acid bacteria were compared for their effect on the immune response to 
rotavirus in children with acute rotavirus gastroenteritis (Majamaa et al. 1995). Among the 
lactic-acid bacteria, LGG therapy was associated with an enhancement of IgA specific 
antibody-secreting cells to rotavirus and serum IgA antibody level at convalescent stage. The 
mean duration of diarrhoea was lowest in children who received LGG as compared to those 
receiving lactic acid bacteria other than LGG. Protection against different serogroups of 
rotavirus and the concentration of IgA in intestinal mucus membranes was not investigated in 
this study. 
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Treatment 
In a double-blind, placebo-controlled study, 301 children between 1 month to 3 years of age 
with acute-onset diarrhoea were investigated (Guandalini et al. 2000). Patients were 
randomised to group A (144 patients) receiving oral rehydration solution plus placebo, or 
group B (147 patients), receiving the same preparation but with a live preparation of LGG (at 
least 1010 CFU/250 ml). After rehydration for the first 4 to 6 hours, patients were offered their 
usual feeding plus free access to the same solution until diarrhoea ceased.  Duration of 
diarrhoea was 71.9±35.8 h in group A as compared to 58.3±27.6 h in group B. In rotavirus-
positive children, diarrhoea lasted 76.6±41.6 h in group A as compared to 56.2±16.9 h in 
group B. Diarrhoea lasted longer than 7 days in 10.7% of group A as compared to 2.7% of 
group B. Hospital stays were significantly shorter for group B than for group A. 
Unfortunately, the effect of LGG in different age groups of the infants and children was not 
analysed. 
 
XI-C- LGG for treatment and prevention of atopic eczema  
Treatment  
The treatment of atopic eczema with probiotics has been investigated in four studies. A 
significant improvement in atopic eczema after 2 months treatment as assessed by SCORAD 
(European Task Force on Atopic Dermatitis 1993) was observed in infants who were given 
probiotic supplemented hydrolysed formula (Isolauri et al. 2000b). LGG and Bifidobacterium 
lactis Bb-12 were equally effective. These studies were flawed by the small number of 
children in each group. Their findings were not replicated in two subsequent larger studies 
carried out by other research groups. They studied the effect of LGG alone or in a mix 
(Viljanen et al., 2005 Allergy, in press) and a combination of L. rhamnosus 19070-2 and  L. 
reuteri DSM 122460 (Rosenfeldt et al. 2003), respectively.  No overall improvement in 
eczema as assessed by SCORAD was noted in these two studies. However, in a subgroup of 
children with IgE sensitization, there was a significant improvement, although the effect was 
moderate. (Viljanen et al., 2005 Allergy, in press; (Rosenfeldt et al. 2003). In another study, 
the treatment of atopic eczema with probiotics was examined in infants who developed 
eczema whilst being exclusively breast-fed (Isolauri et al. 2000a). The infants were weaned to 
probiotic supplemented hydrolysed formula. After 2 months of treatment, SCORAD was 
significantly decreased in the infants who received Bifidobacterium lactis Bb-12 or LGG 
supplemented formula as compared with infants who received unsupplemented hydrolysed 
formula.  
 
Prevention 
The effect of LGG in the prevention of early atopic disease in high risk children, (i.e. with a 
family history of atopy) was investigated (Kalliomaki et al. 2001). LGG was given daily in 
capsules to mothers for 2-4 weeks before expected delivery, and after delivery to the breast-
feeding mothers and directly to the infants (capsule content mixed with the water and given 
with spoon) for 6 months.  In this prospective study from birth, atopic eczema was diagnosed 
at two years of age in 46 of 132 (35%) children. The frequency of atopic eczema was half that 
of the placebo group (15/64; 23%, vs 31/68; 46%). The mechanisms of LGG treatment in the 
treatment of atopic eczema were, however, not clarified in this study. No differences in 
sensitisation were observed between the placebo and probiotic group as the results of skin 
prick tests, and total and specific IgE were similar. The study did not include results with 
regard to cell-mediated immunity. The study group was also evaluated at 4 years of age. 
Atopic eczema was diagnosed on the basis of questionnaire and a clinical examination. 
Fourteen of 53 children who had received LGG had clinical symptoms of atopic eczema as 
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compared to 25 of 54 children in the placebo group (Kalliomaki et al. 2003). There was a 
non-significant tendency for an increase in asthma and pollen allergy among the children of 
the treated group (Niers et al. 2003). Furthermore, the incidence of diagnosed cow milk 
allergy was doubled in the probiotic group (Kalliomaki et al. 2003), although these 
differences were no longer apparent at the age of 4 years. Evidently there is a need for further 
studies that may clarify whether these were chance findings, or if the risk of other atopic 
diseases increases in parallel with a decrease in atopic eczema. 
         
In conclusion, there is no convincingly documented effect of LGG with regard to the 
prevention of any condition. With regard to treatment, short-term effects are demonstrated 
with regard to shortening the duration of acute viral diarrhoea. Conclusive evidence is 
presently lacking with regard to bacterially caused diarrhoea or diarrhoea induced by 
antibiotics. None of the published studies have reported side effects related to the use of LGG, 
other than suggestions of increased allergic sensitisation, but the studies generally focused on 
detecting positive effects rather than on safety. All the studies lack information regarding 
long-term effects and possible changes in the infant intestinal microflora related to LGG 
consumption. When reviewing studies on the effects of LGG in infants and young children it 
is clear that such studies are difficult to verify, since the children are exposed to different 
microorganisms and compliance in using the LGG-containing formula will vary.  
 
XII- LGG for immunocompromised infants and children 
Since LGG has been implicated in systemic infections in severely ill patients, the use of LGG 
for the management of diarrhoea in immunocompromised children cannot be recommended 
and needs further evaluation. The European Society of Pediatric Gastroenterology and 
Hepatology (ESPGHAN) Committee on Nutrition has noted that the available data are not 
sufficient to support the safety of probiotics in newborns, nor in very young infants with 
immature defence systems, immunocompromised infants, premature infants, and infants with 
congenital heart disease (Agostoni et al. 2004).   
 
XIII- Products containing probiotic bacteria, intended for 
consumption by infants and small children – dose 
considerations 
If the concentration of a probiotic in a baby food product is 108 cfu/g powders, this would 
result in a dose of  ~107cfu/g in the prepared food. At present there is no international 
consensus on the number of living probiotic cells that should be consumed per day. In the 
case of a probiotic infant-formula, this food would probably constitute the sole source of 
nutrition, and so the dose of probiotic bacteria per body weight or intestinal volume would be 
considerably higher than that in adults.  It must be remembered that baby food containing 
probiotic bacteria would totally ‘fill’ the GI tract, as opposed to being only a portion of the 
total GI content. Ingestion of 1kg product during one day would give a daily dose of 1010 
bacterial cells. A child of 10kg might have a GI content of 500g, which if the probiotic food 
were the only source of nutrition, would contain a concentration of 107 cfu probiotic 
strain/g,assuming neither growth nor death of the ingested cells. Information concerning 
possible proliferation of the probiotic bacteria during digestion is lacking, both for adults and 
infants. An adult has a GI content of >2000g.  150mL of yoghurt, containing 107cfu/mL, 
would give a probiotic cell density of ∼105.8cfu/mL. In a dried product, such as a milk 
powder, freeze-dried bacteria would not proliferate but could die. After reconstitution, growth 
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of the strain would depend on the temperature, time and also on the available carbohydrate. 
Many products contain carbohydrates other than lactose and therefore the product would give 
a good nutritional source for growth of most probiotic strains. 
 
XIV- Data gaps 
The following data gaps listed below have been identified: 
1. Long-term effects of consumption of LGG  
2. Use of molecular methods for differentiation of Lactobacillus GG from other lactobacilli in 
samples from consumers 
3. Information regarding colonization in the human intestine  
4. Standardised methods for evaluating the concentration of LGG in infants formula and baby 
foods (i.e. the dose) 
5. Standardised methods for assessing of colonization by LGG in intestine 
6. Microbiological examination of the different parts of the intestinal tract in children 
receiving LGG.  Microbiological examination has been performed in samples from faeces, 
representing the microflora in colon, but certainly not the flora in higher regions of the GI 
tract or bacteria adhering to the mucosa 
7. Data regarding use of LGG in infant formula, classified as “food for special medical 
purposes” in infants (0-4 months) with cow’s milk protein and soy allergy 
8. Data regarding use of LGG in infant formula, classified as “food for special medical 
purposes” in infants and children > 4 months 
9. Data regarding use of LGG in baby foods intended for use in healthy infants and children 
between 4 months and 3 years 
10. Independent scientific research 
 
XV- Conclusions 
LGG has been widely studied and characterized in short-term trials, but long-term trials in 
children are lacking.  
LGG seems to have beneficial effects in treatment of viral infectious diarrhoea in infants and 
young children. Furthermore, LGG may have a moderate effect on atopic eczema in IgE-
sensitised children, although this is not yet sufficiently documented and needs to be confirmed 
in further studies. 
There is no consistent scientific evidence of prophylactic effects of LGG, whether for 
diarrhoea or for atopic diseases, or for any other diseases.  
No immediate adverse effects of LGG have been observed in healthy individuals, 
The long-term effects on the microflora of the intestine when LGG is given to small children 
are unknown. 
The long-term effects on the immune function (immune defence, allergy, and autoimmunity) 
of the gut, and systemically, when LGG is given to small children is unknown  
The long-term effect of a heavy, artificial, single-species bacterial load on the newborn infant 
intestine is unknown. 
 
Since there is no documented prophylactic effect of LGG on any diseases in children, there is 
currently no medical indication for supplementing milk substitutes or children’s food with 
LGG. 
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The products assessed in this paper are products intended for daily use (cow’s milk substitutes 
intended for daily use for children who do not tolerate cow’s milk) or regular use (children’s 
food) and not for short-term specific treatment. Furthermore, the targeted consumer group 
includes, and the products are in part even primarily intended for, children below the age of 
one year. These two aspects demand particular consideration with regard to the unknown 
effects of long-term treatment with live bacteria on the ecology of the microflora and on the 
immune system, particularly since both these systems have not yet fully matured in infants 
and small children. Thus if future studies were to document any prophylactic effects of LGG 
with regard to any disease, the unknown, long-term possible adverse effects on the immune 
system and on the microbial ecology would still need to be considered in the age group below 
4 years, and especially below the age of one (theoretically, the younger the child, the larger 
the potential for long-term effects due to immaturity).      
  
These conclusions apply to probiotic products intended for use in infants and small children, 
and they do not necessarily apply to probiotic products intended for older children and adults 
(age groups in whom the digestive and immunological systems are considered mature). 
Neither do these conclusions apply to products intended for short-term treatment of a disease 
in which a documented effect has been shown (e.g. acute diarrhoea). However, the products 
that the group has been asked to evaluate do not fall into the two above-mentioned categories. 
 
XVI- Recommendations*
1. LGG is, based on generally recognized data, not suitable for use in infant formula intended 
for daily use. 
2. LGG is, based on generally recognized data, not suitable for use in infant formula classified 
as food for special medical purposes for infants 0-4 months old with the diagnosis “ cow’s 
milk protein and soy allergy”. 
3. LGG is, based on generally recognized data, not suitable for use in infant formula classified 
as food for special medical purposes for infants between 4 months and 1 year, nor for children 
>1 year if it is to be given several times per day. 
4.  LGG is, based on generally recognized data, not suitable for use in baby foods for healthy 
children >1 year if the food is intended for use several times per day. 
 
 
 
 
 
 
 
                                                 
* LGG er, basert på generelt anerkjente data, ikke egnet til å inngå i morsmelkerstatninger beregnet på daglig 
bruk til spedbarn. 
LGG er, basert på generelt anerkjente data, ikke egnet til å inngå i morsmelkerstatninger klassifisert som 
medisinske næringsmidler til sped barn (0 – 4 måneder) med diagnosen kumelkallergi eller soyaallergi. 
LGG er, basert på generelt anerkjente data, ikke egnet til å inngå i morsmelkerstatninger klassifisert som 
medisinske næringsmidler til spedbarn mellom 4 måneder og 1 år og heller ikke til barn > 1 år hvis det skal gis 
flere ganger daglig. 
LGG er, basert på generelt anerkjente data, ikke egnet til å inngå i  
barnemat beregnet på bruk til friske småbarn > 1 år hvis maten er beregnet til bruke flere ganger daglig. 
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XI- Page 13. In our opinion, a positive health effect of LGG with respect to atopic eczema is 
not documented and needs further investigation. 
Since some studies have shown that the consumption of food containing LGG may 
significantly reduce the risk of nosocomial diarrhoea in hospitalized infants, particularly 
nosocomial rotavirus gastroenteritis, we have changed this phrase in our risk assessment: 
 “In conclusion, there is no convincing documented effect of LGG with regard to the 
prevention of any condition” 
 
to the following: 
 
“In conclusion, there is no convincing documented effect of LGG with regard to the 
prevention of atopic eczema. However, prophylactic LGG supplementation has been shown to 
reduce the risk of nosocomial diarrhoea in hospitalized infants”. 
 
XV Page 14.  Since there is some evidence of prophylactic effect of LGG supplementation on 
nosocomial rotavirus gastroenteritis we have changed the phrase: 
“Since there is no documented prophylactic effect of LGG on any diseases in children, there 
is currently no medical indication for supplementing milk substitutes or children’s food with 
LGG”,  
 
to the following: 
 
“There is some evidence for a prophylactic effect on diarrhoea in hospitalized children. 
However, apart from some at risk hospitalized children, there is currently no medical 
indication for supplementing milk substitutes or children’s food with LGG, neither in order to 
prevent atopic eczema nor for daily use in healthy children or children who are intolerant to 
cow’s milk or soy formula.” 
 
